<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection and Population Health</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/275BDF7A-7C42-40AE-A49E-FD1E2CD03215"><gtr:id>275BDF7A-7C42-40AE-A49E-FD1E2CD03215</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Sabin</gtr:surname><gtr:orcidId>0000-0001-5173-2760</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3D1BE2EA-694D-41BA-8055-D1DB7D3D3658"><gtr:id>3D1BE2EA-694D-41BA-8055-D1DB7D3D3658</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Nicholas</gtr:otherNames><gtr:surname>Phillips</gtr:surname><gtr:orcidId>0000-0003-2384-4807</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F4C48495-1923-4707-89F9-8E633268BD2A"><gtr:id>F4C48495-1923-4707-89F9-8E633268BD2A</gtr:id><gtr:firstName>Deenan</gtr:firstName><gtr:surname>Pillay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/168CFD16-EA26-4A8A-B3E6-5E11BD817F3E"><gtr:id>168CFD16-EA26-4A8A-B3E6-5E11BD817F3E</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Tyre</gtr:otherNames><gtr:surname>Dunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900274"><gtr:id>78A40562-3247-48E5-BED2-74E39B802692</gtr:id><gtr:title>The clinical outcomes, response to treatment and epidemic dynamics of HIV-1 in the UK</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900274</gtr:grantReference><gtr:abstractText>The characteristics of individuals with HIV in the UK are changing with a much greater number of those living with HIV being women. Treatments for HIV are now very effective and many people infected with the virus are able to live almost normal lives. As a result, not only is the HIV-infected population growing older, but many of the women are starting their own families. Even if these women do not yet require treatment for their own health, they may be treated for short periods of time to prevent their babies from becoming infected with HIV. This treatment is very effective and only a very small number of HIV-infected babies are now born in the UK each year. Treatment may be further complicated among individuals who are also infected with hepatitis C or B virus ? these individuals may require earlier treatment and/or different drug combinations than those who are only infected with HIV.
 
Despite the benefits of treatment, the drugs may still occasionally fail in an individual. This may be because the individual develops side effects to the drugs, or that they find it difficult to take their drugs at exactly the same time every day. When treatments fail, the virus may become resistant to the drugs that the patient is receiving, and this may have knock-on effects for their future treatment choices. Consequently, doctors have started to change the way in which they treat HIV-infected people; for example, treatment may be started earlier and different drug combinations may be used which aim to reduce the risk of side effects, whilst minimising the risk that a patient?s virus will become resistant. In order to plan the future care for these individuals, we need to monitor the use of treatment in HIV-infected persons, and the outcomes of those who receive it. 

Two large ongoing studies in the UK, the UK CHIC Study and the UK HDRD, have been monitoring outcomes (e.g. use of treatment, AIDS events, deaths, development of resistance) in HIV-infected persons since 2001. This proposal requests funding to continue to expand and monitor these cohorts so that the information they provide remains timely and accurate. In addition to monitoring outcomes, we also plan to investigate whether treatment received during pregnancy has any long-term effects on the mother?s health, and whether infection with hepatitis B or C accelerates the progression of HIV disease, or reduces the benefits of treatments.</gtr:abstractText><gtr:technicalSummary>The use of highly active antiretroviral therapy (HAART) has had a major impact on the health of HIV-infected individuals in the developed world and, as a result, life expectations of those infected with HIV have started to approach those seen in the general population. However, treatment paradigms are changing and over the next five years we expect to see changes in the drugs/drug combinations used, the order in which they are sequenced and the CD4 count at which treatment is started. However, the development and transmission of resistant HIV remains a threat to successful treatment. Furthermore, those living with are now older, a greater proportion are women (many of whom are becoming pregnant and receiving treatment to prevent transmission of HIV to their baby) and many are co-infected with viral hepatitis; these factors may complicate the management of those with HIV. In order to plan the need for health-care services and to understand the need for new antiretroviral drugs in HIV-infected persons, it is important to continue to monitor the outcomes of treatment in this population, including the incidence and patterns of drug resistance, and to determine the degree to which the efficacy of future drugs is likely to be compromised by resistance development. 

The UK Collaborative HIV Cohort (CHIC) Study and UK HIV Drug Resistance Database (UK HDRD) were initiated in 2001 to monitor the uptake and response to HAART among individuals with HIV in the UK, and the development of resistance in these individuals. The main objective of this programme grant application is to continue to follow these two large cohorts (with expansion where possible so that they continue to follow a large and geographically representative group of patients) with the aim of providing timely information on the changing trends over time. In addition, several other questions have arisen which must now be addressed, relating particularly to the use of treatment during pregnancy and the impact of long-term co-infection with hepatitis viruses. Thus, we propose to develop five complementary themes of research (ongoing monitoring of outcomes; understanding the transmission and persistence of resistance; understanding the molecular epidemiology of the UK epidemic; describing the impact on women of antiretroviral treatment received during pregnancy; and describing the impact of co-infection with hepatitis B/C on HIV outcomes). Each theme will include a series of co-ordinated projects covering questions across the broad scientific area.</gtr:technicalSummary><gtr:fund><gtr:end>2014-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1876886</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HIV-CAUSAL (Harvard University plus others)</gtr:description><gtr:id>C629528A-6ACB-4027-8CEC-31F637D457BA</gtr:id><gtr:impact>Several publications in high impact journals, all are listed in appropriate section</gtr:impact><gtr:outcomeId>GSen8wEKTPn-1</gtr:outcomeId><gtr:piContribution>Intellectual input into study design and analysis; provision of datasets; writing manuscripts</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>HCV Research UK Launch meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6853B6DC-7C61-4655-9DE7-EDCE280E8995</gtr:id><gtr:impact>Gave talk to investigators of new HCV cohort study about experiences in similar studies in HIV so that we could cross-fertilise ideas

None as yet</gtr:impact><gtr:outcomeId>rAf6xiPcTNw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK HIV Community Advisory Board</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>588E5E2E-6F42-4E73-8E56-D83BD967E458</gtr:id><gtr:impact>Members of the study team provided information about the UK CHIC and UK HDRD studies to 30 representatives from the UK HIV Advisory Group, and answered questions about the studies afterwards.

Discussions from this meeting led to several agreements for new analyses at the request of the HIV patient community.</gtr:impact><gtr:outcomeId>Vde6fZEEWZc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>WHO HIV ResNet HIV Drug Resistance Surveillance Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7D493A2D-C9AA-470C-B153-A28F6A101EBE</gtr:id><gtr:impact>Provided statistical input on a debate on the use of the finite population correction in survey research and sampling strategies for surveys to estimate the prevalence of transmitted HIV drug resistance

None as yet.</gtr:impact><gtr:outcomeId>P7zf28dYHbo</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BHIVA Monitoring Guidelines</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>BHIVA Monitoring Guidelines</gtr:guidelineTitle><gtr:id>8AB5A57F-0C31-406C-B84F-DC1A1D9E67A9</gtr:id><gtr:outcomeId>gWjb2zdyif5</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in treatment guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Various guidelines for monitoring and treatment of patients with HIV</gtr:guidelineTitle><gtr:id>10CC9C77-2DD6-4B60-944A-4594D29B819D</gtr:id><gtr:outcomeId>PkgoFrKYSL7</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BHIVA treatment guidelines</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>BHIVA Treatment Guidelines</gtr:guidelineTitle><gtr:id>98F03082-0F2B-4AB3-AAD6-B92D77135581</gtr:id><gtr:outcomeId>R8k4Ci9rHyB</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The UK CHIC database is expanded on a yearly basis through this grant</gtr:description><gtr:id>4FB2AF34-D7DC-4830-A9AB-B6533B16D0A2</gtr:id><gtr:impact>Ongoing research collaborations with external organisations</gtr:impact><gtr:outcomeId>Yfv8YnkNa33</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UK CHIC database</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7EF53095-D60E-4B54-8A0B-F50479459320</gtr:id><gtr:title>Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f48e17fbd8a0a2d8d5cdceaef1042b6"><gtr:id>9f48e17fbd8a0a2d8d5cdceaef1042b6</gtr:id><gtr:otherNames>Price H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>jfx3rC9fAJ5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1943F50D-19FD-4455-A2D3-DC22054B61B8</gtr:id><gtr:title>Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3b6ec49e9bbb39be0345d4b21b60dbf"><gtr:id>b3b6ec49e9bbb39be0345d4b21b60dbf</gtr:id><gtr:otherNames>Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>546102d39f9ae4.24460317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85BC4559-7A2D-476C-B5B5-E4AF671D8BE4</gtr:id><gtr:title>Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>54610389059a55.29660583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ABE0F48-EA39-4584-8388-962505312756</gtr:id><gtr:title>Automated analysis of phylogenetic clusters.</gtr:title><gtr:parentPublicationTitle>BMC bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e26fd1d275edccf846e4efd533484ad"><gtr:id>5e26fd1d275edccf846e4efd533484ad</gtr:id><gtr:otherNames>Ragonnet-Cronin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2105</gtr:issn><gtr:outcomeId>546229db9e6456.55826393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56A27DB3-85BE-4DB4-A1E2-5AEAF624649C</gtr:id><gtr:title>Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>546229dbe73c29.09820792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3B228E1-3770-42E7-BAF9-2EB7C9CABDF8</gtr:id><gtr:title>Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0273dd103e257f1782539313e806d79c"><gtr:id>0273dd103e257f1782539313e806d79c</gtr:id><gtr:otherNames>Cozzi-Lepri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>fhxdGYiuLpH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4A6B8CD-5B67-442D-9D04-FAEC22F8A34A</gtr:id><gtr:title>Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66880df30e269a3e929a7c58fe3ba252"><gtr:id>66880df30e269a3e929a7c58fe3ba252</gtr:id><gtr:otherNames>Santoro MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_12455_25_23668660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46566FFF-4FA8-4B70-9C74-B3685F8F4389</gtr:id><gtr:title>Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd93323ca1f87347a200b0499bfb0deb"><gtr:id>bd93323ca1f87347a200b0499bfb0deb</gtr:id><gtr:otherNames>Fox J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>Ex8WqunDRDo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB63D987-E219-46FB-B359-66C82DA1A4AF</gtr:id><gtr:title>Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART).</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>ZX1RutJLmyZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F75B5838-2F35-4988-8174-24A13C1F2753</gtr:id><gtr:title>Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee525c2e3a0983da94ca3d109d1764b"><gtr:id>9ee525c2e3a0983da94ca3d109d1764b</gtr:id><gtr:otherNames>UK Collaborative Group on HIV Drug Resistance</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_12455_25_22915687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68021E84-76D1-44E4-884E-82F1D16FAF3B</gtr:id><gtr:title>Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee525c2e3a0983da94ca3d109d1764b"><gtr:id>9ee525c2e3a0983da94ca3d109d1764b</gtr:id><gtr:otherNames>UK Collaborative Group on HIV Drug Resistance</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>PBQowxiqPyw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FD8D586-3688-4B5A-A255-CD888C2E1D45</gtr:id><gtr:title>The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abe0206decb5898e085084e699c825fa"><gtr:id>abe0206decb5898e085084e699c825fa</gtr:id><gtr:otherNames>Cain LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12455_25_22546987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBD85786-D89B-41A7-A01B-E2FBB142C2B9</gtr:id><gtr:title>Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c36f1492c05290516a79c33fee1ea4b"><gtr:id>5c36f1492c05290516a79c33fee1ea4b</gtr:id><gtr:otherNames>Mocroft A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_12455_25_24137103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8836CE27-C87C-469B-9995-ED25E957FA0B</gtr:id><gtr:title>Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57c30723062483d637e0ebc9fff97497"><gtr:id>57c30723062483d637e0ebc9fff97497</gtr:id><gtr:otherNames>Waters L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>54622bc2bd8d74.32230172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E23FFED-4D29-40F8-8F71-453B310D6523</gtr:id><gtr:title>Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5462271c04f6a1.05749434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88B43DED-45F1-4BEB-8220-890C28D02C16</gtr:id><gtr:title>Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/801b89bcbbadfe35293e42012e24ca43"><gtr:id>801b89bcbbadfe35293e42012e24ca43</gtr:id><gtr:otherNames>Barber TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>546229dc17a177.82964105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>535A7625-FDE0-49C3-886D-B1430C49AD0F</gtr:id><gtr:title>The increasing genetic diversity of HIV-1 in the UK, 2002-2010.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee525c2e3a0983da94ca3d109d1764b"><gtr:id>9ee525c2e3a0983da94ca3d109d1764b</gtr:id><gtr:otherNames>UK Collaborative Group on HIV Drug Resistance</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5462275253f881.48586982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17332880-236C-4C7C-8982-3D3F4B0C5BCE</gtr:id><gtr:title>HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9859179eab8d2f5d7df659dae68e5864"><gtr:id>9859179eab8d2f5d7df659dae68e5864</gtr:id><gtr:otherNames>Dolling DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_12455_25_23074305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>155F9C16-299A-4591-9C35-145A3F86221B</gtr:id><gtr:title>CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ae7906330165e2a6517354671ff3490"><gtr:id>7ae7906330165e2a6517354671ff3490</gtr:id><gtr:otherNames>Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_12455_25_22448150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6A1B9DE-C5B7-4503-9BE5-DC844D44970E</gtr:id><gtr:title>Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56d990ddb469e1.86372148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEAC2DD3-D411-4885-A600-5814DCD98064</gtr:id><gtr:title>A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/282ae484e5c075253c677437743d1964"><gtr:id>282ae484e5c075253c677437743d1964</gtr:id><gtr:otherNames>Patterson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5a2fd73d3f69c2.32890936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C359907-1459-4C45-AE99-30B99DB5C9CB</gtr:id><gtr:title>Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/695a4578e393f7e7c4b9cab9bcec3ac3"><gtr:id>695a4578e393f7e7c4b9cab9bcec3ac3</gtr:id><gtr:otherNames>Dolling D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_12455_25_22151684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A849D58-798D-4E9E-A91A-ABFC676ACFA0</gtr:id><gtr:title>Clinical epidemiology of HIV-associated end-stage renal failure in the UK.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>54623e78ad9885.07371630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>503833FB-3BDF-487D-A5A2-D859078AD2BF</gtr:id><gtr:title>Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b18ef1bb71f9d1c5b2422991e2bebc17"><gtr:id>b18ef1bb71f9d1c5b2422991e2bebc17</gtr:id><gtr:otherNames>Hughes RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>546229dc3ba775.17076822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BCDDEE5-7989-405C-9F32-0D39C52D4FC0</gtr:id><gtr:title>Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9859179eab8d2f5d7df659dae68e5864"><gtr:id>9859179eab8d2f5d7df659dae68e5864</gtr:id><gtr:otherNames>Dolling DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>doi_55f983983d8baac1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23A9516D-EAA9-46DA-935C-1700CF654F18</gtr:id><gtr:title>The impact of HIV drug resistance testing on changes to treatment.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>546229db740234.61101242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C29C2D46-D2D0-4764-81A2-BE93C72EFA20</gtr:id><gtr:title>Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f278c39a50463e907833d72effcc42b3"><gtr:id>f278c39a50463e907833d72effcc42b3</gtr:id><gtr:otherNames>Assoumou L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>p8f6WebGaGC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ABBA0D8-888F-47E5-9F44-94621C40BA8F</gtr:id><gtr:title>The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0f911b1a5eb21f1fd0ce082a070f9f8"><gtr:id>c0f911b1a5eb21f1fd0ce082a070f9f8</gtr:id><gtr:otherNames>Bulteel N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>pm_12455_25_24055802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46939E4F-1869-40BD-9EA5-70FCFDBE71F7</gtr:id><gtr:title>Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5462271c4d84b6.69221181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54597768-F606-42C3-9605-A8728A704AD2</gtr:id><gtr:title>Long-term mortality in HIV-positive individuals virally suppressed for &amp;gt;3 years with incomplete CD4 recovery.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5754a6c189699f93dc0d4ebf6bd186d"><gtr:id>a5754a6c189699f93dc0d4ebf6bd186d</gtr:id><gtr:otherNames>Engsig FN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>546103897a5103.02782013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5F48830-187F-4D64-835F-2E5794E1FC56</gtr:id><gtr:title>Data linkage reduces loss to follow-up in an observational HIV cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/714c11cae3bdf9319cae1a059307588e"><gtr:id>714c11cae3bdf9319cae1a059307588e</gtr:id><gtr:otherNames>Hill T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>54622bc2e1bfc7.39160065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A389756B-5374-47A9-95EB-F385DB8C651D</gtr:id><gtr:title>HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f213c1c9e7860c6d84b3dac6b1ef48e3"><gtr:id>f213c1c9e7860c6d84b3dac6b1ef48e3</gtr:id><gtr:otherNames>Chilton DN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>aUPUUFfDNrt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1E303BD-9885-4515-8346-4CF7727C53E4</gtr:id><gtr:title>Predicting virological decay in patients starting combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d0ae6e7a98bbd0f130691f9c6ce1e21"><gtr:id>5d0ae6e7a98bbd0f130691f9c6ce1e21</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (UK CHIC) Writing Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>585d65df4b1b92.70089223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B16E73E-4653-4513-8F81-1A3353F0CA90</gtr:id><gtr:title>Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/154626858cc42f66f33a93cb72762480"><gtr:id>154626858cc42f66f33a93cb72762480</gtr:id><gtr:otherNames>Garvey L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>546229db4ae482.79853639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>820720F9-2E0C-4DEF-9655-69D21899BD7E</gtr:id><gtr:title>Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>585d559b450019.24417085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5F6D255-05D4-4D17-B8BB-444F1950F501</gtr:id><gtr:title>Development and application of a new measure of engagement in out-patient HIV care.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/365192f3fdd9512e949582a17de15e1e"><gtr:id>365192f3fdd9512e949582a17de15e1e</gtr:id><gtr:otherNames>Howarth AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>585d39b4924c22.65699587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9586279-B177-4496-B9ED-F49E976100F4</gtr:id><gtr:title>Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25dcd7f9bafbbcd6f229ae06da737fee"><gtr:id>25dcd7f9bafbbcd6f229ae06da737fee</gtr:id><gtr:otherNames>Prosperi MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>iggHDXtHnmh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C81B46AD-79E7-4DE2-B83F-55817D8F0A4E</gtr:id><gtr:title>Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ded355ac2c46668fd5d3aaae309792d2"><gtr:id>ded355ac2c46668fd5d3aaae309792d2</gtr:id><gtr:otherNames>del Amo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_12455_25_22460971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB9217E9-43E4-4E25-8AE3-08EBA87DBA95</gtr:id><gtr:title>Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a35586be0a5b78e8a4231529ab32ca2"><gtr:id>1a35586be0a5b78e8a4231529ab32ca2</gtr:id><gtr:otherNames>O'Connor JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>546227522db689.11789330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>850A6EF4-60D0-4843-8E9D-212F95EF48A6</gtr:id><gtr:title>Non-uptake of highly active antiretroviral therapy among patients with a CD4 count &amp;lt; 350 cells/?L in the UK.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64fa8c17b9aa548557c762139ce65be3"><gtr:id>64fa8c17b9aa548557c762139ce65be3</gtr:id><gtr:otherNames>Kober C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>546229dbc35314.21327268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC791564-1C7F-43BF-A216-F2F7D4D2FC57</gtr:id><gtr:title>Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5462271c2863f7.14698408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1366CF7-7FCF-4248-86E7-8CA26CF1E78E</gtr:id><gtr:title>Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91e9e79ddc1ff12466df8f0af4fb3c40"><gtr:id>91e9e79ddc1ff12466df8f0af4fb3c40</gtr:id><gtr:otherNames>Caniglia EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>546102d3724e64.09761062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0E29761-1591-45CE-94FD-69A1EF30C86D</gtr:id><gtr:title>The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/743184f900cf7f05341330efd5ab8b02"><gtr:id>743184f900cf7f05341330efd5ab8b02</gtr:id><gtr:otherNames>Donegan KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_12455_25_22300840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F883E746-52D3-4207-A5CA-E1FED3763316</gtr:id><gtr:title>The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3583e3b7afc8611b8cd7c4a38660e23"><gtr:id>c3583e3b7afc8611b8cd7c4a38660e23</gtr:id><gtr:otherNames>Harrison L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>d5MPFLd24kw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F05869B8-CB74-4C89-BE2A-25EA2C2BB7C4</gtr:id><gtr:title>Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>54622bc3130425.57864261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C719D07B-11F7-438A-8049-38B122068114</gtr:id><gtr:title>Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57c30723062483d637e0ebc9fff97497"><gtr:id>57c30723062483d637e0ebc9fff97497</gtr:id><gtr:otherNames>Waters L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>546103892d5847.61081802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46AC9C68-3D8B-45B1-928F-3061784946CE</gtr:id><gtr:title>Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f278c39a50463e907833d72effcc42b3"><gtr:id>f278c39a50463e907833d72effcc42b3</gtr:id><gtr:otherNames>Assoumou L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>hQPzEdYbm47</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D9F0DF6-A747-4E71-9211-7CE9E3285CB3</gtr:id><gtr:title>Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35559fb783c85c89aeffc68a0c2d55af"><gtr:id>35559fb783c85c89aeffc68a0c2d55af</gtr:id><gtr:otherNames>Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>izcUsxbRbLL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91E8CD19-77AB-4060-8197-F1C354508A27</gtr:id><gtr:title>Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d0e4078101e2913852def3cc79eff29"><gtr:id>0d0e4078101e2913852def3cc79eff29</gtr:id><gtr:otherNames>Hu? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>54610244018358.67294120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7898E74B-13C3-4674-B231-DC25CF22DC48</gtr:id><gtr:title>A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/372c212584ac2efb0a65f6beb91c0c0d"><gtr:id>372c212584ac2efb0a65f6beb91c0c0d</gtr:id><gtr:otherNames>Ragonnet-Cronin ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>585d681f3f95d6.06688653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DED34EF4-EF89-4481-82D1-07CFAFDE8EDF</gtr:id><gtr:title>Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56d990ddd8def3.69683509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F49A7C2D-AB29-47BF-98EF-94A8C0E6B6C3</gtr:id><gtr:title>When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7372a0a0e63d31deab6b40a83d243c44"><gtr:id>7372a0a0e63d31deab6b40a83d243c44</gtr:id><gtr:otherNames>HIV-CAUSAL Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>MfKjw1q14DT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90C2F5F7-5242-48D8-BFF9-C4BF97109C12</gtr:id><gtr:title>HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b0e0090ceccbbd7fd17b20da7528b7"><gtr:id>47b0e0090ceccbbd7fd17b20da7528b7</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (CHIC) Study Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>chmEmtpGCGc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B3562A4-44B3-4B88-8349-3DE05C6619F1</gtr:id><gtr:title>Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/538dc621cb901e80c1188bb06941ac87"><gtr:id>538dc621cb901e80c1188bb06941ac87</gtr:id><gtr:otherNames>De Luca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12455_25_23315324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0A6B162-7C78-49DF-816A-7257DB73A17F</gtr:id><gtr:title>Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b9c01792a7d27fee5dc4b30b44344ea"><gtr:id>0b9c01792a7d27fee5dc4b30b44344ea</gtr:id><gtr:otherNames>Takebe Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>54610243cedd56.80446423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E2AB2FA-DE78-4705-8907-1A5D3F351795</gtr:id><gtr:title>Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f922cffe072fd13496e024ca3b4ee31f"><gtr:id>f922cffe072fd13496e024ca3b4ee31f</gtr:id><gtr:otherNames>Castro H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>pm_12455_25_22416878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94FD209F-4870-42A0-926D-A02CCE868608</gtr:id><gtr:title>Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/628b4b467257f0b8acbc7ade51f7a1a8"><gtr:id>628b4b467257f0b8acbc7ade51f7a1a8</gtr:id><gtr:otherNames>Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12455_25_23225900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>738B3ABF-03E5-4E58-BB45-6D0BDB3AEB84</gtr:id><gtr:title>End-stage kidney disease and kidney transplantation in HIV-positive patients: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3110d40d6f2e49b9e9f39f461ad254c0"><gtr:id>3110d40d6f2e49b9e9f39f461ad254c0</gtr:id><gtr:otherNames>Gathogo E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>54610243a61f76.59250460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5339CE2E-135F-4A85-8126-D1237AA0FCDE</gtr:id><gtr:title>The contribution of viral genotype to plasma viral set-point in HIV infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a6f6588856978d76ed6abeb8216566a"><gtr:id>8a6f6588856978d76ed6abeb8216566a</gtr:id><gtr:otherNames>Hodcroft E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>546226f1c35976.97213620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>217DBE98-1184-431D-AD54-07338C1BC3E4</gtr:id><gtr:title>The HIV-1 subtype C epidemic in South America is linked to the United Kingdom.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/252e4dea05f5ae2585a70c3e641bab74"><gtr:id>252e4dea05f5ae2585a70c3e641bab74</gtr:id><gtr:otherNames>de Oliveira T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pV6DVSLMooR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79FB6FEA-0B3E-4367-9CAE-45E34CB2390D</gtr:id><gtr:title>Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46286eef88a09fac06d9580bfa9a952e"><gtr:id>46286eef88a09fac06d9580bfa9a952e</gtr:id><gtr:otherNames>Gilson RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>54623e788684f7.39008132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B9B4946-A867-4AB6-BAF3-F2A56DCF9F7C</gtr:id><gtr:title>Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e7ffd30d3d558be5c0122ed5a8f57f0"><gtr:id>8e7ffd30d3d558be5c0122ed5a8f57f0</gtr:id><gtr:otherNames>Koning FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_12455_25_23386260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DF46CFB-266E-49EA-98A7-F2838825EC36</gtr:id><gtr:title>Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a90b45f679d889fd75b95b5af0f57380"><gtr:id>a90b45f679d889fd75b95b5af0f57380</gtr:id><gtr:otherNames>Wittkop L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>KCM6w2VcZtX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3900253D-3D02-4C9A-95F3-927A39CC0BA1</gtr:id><gtr:title>Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60e563cdcf9df64aa0ffb7a1afb09595"><gtr:id>60e563cdcf9df64aa0ffb7a1afb09595</gtr:id><gtr:otherNames>Huntington S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>doi_55faa1aa1eeab4c3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70A680C1-5226-4242-B131-5535D8174C23</gtr:id><gtr:title>Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c926053cd3c7f247fa364994945f7609"><gtr:id>c926053cd3c7f247fa364994945f7609</gtr:id><gtr:otherNames>Booth JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>56d990dc23b1a4.33863097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E698BCA0-656D-47A4-AF99-D4E8025DC562</gtr:id><gtr:title>REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care</gtr:title><gtr:parentPublicationTitle>Health Services and Delivery Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81faae467a1abeb3ea8a472699228491"><gtr:id>81faae467a1abeb3ea8a472699228491</gtr:id><gtr:otherNames>Howarth A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a2fd73038af05.52257640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E553A374-72EF-44BC-8942-09EB1999AA43</gtr:id><gtr:title>Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f48e17fbd8a0a2d8d5cdceaef1042b6"><gtr:id>9f48e17fbd8a0a2d8d5cdceaef1042b6</gtr:id><gtr:otherNames>Price H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12455_25_23145150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88BA3BCA-D18D-4D0E-A415-141AECC73FBD</gtr:id><gtr:title>The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60e563cdcf9df64aa0ffb7a1afb09595"><gtr:id>60e563cdcf9df64aa0ffb7a1afb09595</gtr:id><gtr:otherNames>Huntington S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d990dc99ea88.69954376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E876E6FA-8083-46ED-B5D1-BD8F4084688E</gtr:id><gtr:title>Late diagnosis in the HAART era: proposed common definitions and associations with mortality.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f61577ce5353e21eebcd751fd76540c9"><gtr:id>f61577ce5353e21eebcd751fd76540c9</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (UK CHIC) Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>CrywWzC5wPU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B406358-72D1-4D6C-A01D-C2C38F1D247D</gtr:id><gtr:title>Persistence of HIV-1 transmitted drug resistance mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f922cffe072fd13496e024ca3b4ee31f"><gtr:id>f922cffe072fd13496e024ca3b4ee31f</gtr:id><gtr:otherNames>Castro H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12455_25_23904291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6891CB8-94CD-4B1E-B788-34F659298218</gtr:id><gtr:title>HLA B*5701 status, disease progression, and response to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dbd487b9375405800430d15de0afeed"><gtr:id>9dbd487b9375405800430d15de0afeed</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort Study Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>doi_55f983983d948d36</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>670CFA92-7AEE-4728-99C7-B22097A2D398</gtr:id><gtr:title>Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/737902126252eeca216b14d33630e096"><gtr:id>737902126252eeca216b14d33630e096</gtr:id><gtr:otherNames>Foster GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546103895572b2.64170653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>321AA20C-C90D-4317-9A8B-FA679D8BF87B</gtr:id><gtr:title>The incidence of AIDS-defining illnesses at a current CD4 count = 200 cells/?L in the post-combination antiretroviral therapy era.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c36f1492c05290516a79c33fee1ea4b"><gtr:id>5c36f1492c05290516a79c33fee1ea4b</gtr:id><gtr:otherNames>Mocroft A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_12455_25_23921881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CD2DD25-0BE7-4A91-98F3-AEC929FCFF53</gtr:id><gtr:title>Renal tubular disease in the era of combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d426d779c840a490da55f26dbb7b7238"><gtr:id>d426d779c840a490da55f26dbb7b7238</gtr:id><gtr:otherNames>Hamzah L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d990dd630825.33172556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF034C2E-D141-41BB-9174-F9D923618ECB</gtr:id><gtr:title>Risk of triple-class virological failure in children with HIV: a retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e54fdd87d76e82626db57fd0593f95e"><gtr:id>5e54fdd87d76e82626db57fd0593f95e</gtr:id><gtr:otherNames>Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>rLp1DpXYi8F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D801D3C5-6242-4D5B-98CA-96375030E328</gtr:id><gtr:title>Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f78916ca445ce7ca828997daa4a8303"><gtr:id>0f78916ca445ce7ca828997daa4a8303</gtr:id><gtr:otherNames>Huntington SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>DPfCdvoeqzh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B36DE3CC-35C2-4841-9D5E-F113BA07A947</gtr:id><gtr:title>Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/801b89bcbbadfe35293e42012e24ca43"><gtr:id>801b89bcbbadfe35293e42012e24ca43</gtr:id><gtr:otherNames>Barber TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>doi_55faa1aa1ee1b372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8A85ECA-ECEA-47C8-94B3-93FAFE98944B</gtr:id><gtr:title>The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e92b49e0e6e3d90f1828b5299dbf67bd"><gtr:id>e92b49e0e6e3d90f1828b5299dbf67bd</gtr:id><gtr:otherNames>Samuel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5462275276d9b1.39601372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF050A85-390E-45CB-AA9C-CA72118AFE2A</gtr:id><gtr:title>The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf9fce5f75d358dfd61d4fb5eb850393"><gtr:id>bf9fce5f75d358dfd61d4fb5eb850393</gtr:id><gtr:otherNames>Mackie NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12455_25_24157905</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900274</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>